1. Role of Unani Medicine as Adjuvant therapy in Chronic & Incurable Diseases
Prof. S. Shakir Jamil
Director General
CCRUM, Department of AYUSH
New Delhi
10th Knowledge Millenium Summit-2013
“Curing the Incurables: Sharing of Innovation”
16th January, 2013, Vigyan Bhavan, New Delhi

2. Origin & Caravan Unani System of Medicine originated from Greece
The philosophical doctrines of the System was laid down by Hippocrates. ( BC)
Arab, Central Asian and European countries contributed to the system.
From Central Asia Unani Medicine traversed to India

3. Present Scenario
Today, India is the world leader in Unani Medicine having largest set up of educational, healthcare and research facilities.
Unani medicine is also recognized, practiced and popular in Pakistan, Bangladesh, Malaysia, Sri Lanka and South Africa.
Also Practiced in Kuwait, Dubai & Saudi Arabia etc.

4. Fundamental concepts Tabiyat (Medicatrix naturae) Mizaj (Temperament)
Akhlat (Body Humours)
Usool-e- Ijaj (Principles of treatment) including Ilaj- bit-Tadbir (Regimenal Therapy)

5. Research & Development
CCRUM
Central Council for Research in Unani Medicine (CCRUM) was established by Government of India as apex organization for Research and Development activities in Unani System of Medicine in 1979.
The Council is an autonomous organization under Department of AYUSH, Ministry of Health & Family Welfare, Govt of India.

7. Central Council for Research in Unani Medicine

8. CCRUM - Mandate Research in Unani Medicine on scientific lines.
To initiate, aid, develop and coordinate scientific research of Unani Medicine.
To finance researches meant for furtherance of objective of the CCRUM.
To exchange information with other institutions.
To prepare and publish literature on Unani medicine. 8 8

9. Research Programmes Pre-clinical/Safety Studies Clinical Research
Fundamental aspects of Unani Medicine
Drug Standardization including SOPs for Unani drugs
Literature including Medico-historical Research
Ethno-botanical Survey, Collection and Cultivation of Unani Medicinal Plants
IEC and other Research oriented programmes

10. Pre-Clinical & Clinical Research
Pharmacological action/safety evaluation 22 drugs
Number of diseases clinically studied 22
Clinical trials completed drugs
Number of drugs under trial 30

11. Validation of Pharmacopoeal drugs
Validation of safety & efficacy of Unani pharmacopoeial
Drugs.
Number of formulations 25
Number of diseases under study 10

12. Leads in Clinical Research
Bars (Vitiligo)
Naar-e- Farsi (Eczema)
Taqashshur-e-Jild (Psoriasis )
Zeequn-Nafas (Bronchial asthma )
Zaght-ud- Dam Qawi (Hypertension)
Daa-ul-Feel (Filariasis)
Iltehaab-e-Mafasil (Rheumatoid arthritis)
Iltehaab-e-Tajaweef-e-Aanaf (Sinusitis)

13. Validation of Unani Fundamentals
Study on susceptibility of acquiring diseases in relation to
Mizaj (temperament).
Study on molecular interpretation of individual
temperament at CRIUM, Hyderabad
in collaboration
with Center for Cellular and Molecular Biology, CSIR, Hyderabad.

14. Drug Standardization including SOPs for Unani drugs
Unani single drugs standardized 298
SOPs developed for compound Unani formulations

15. Patents
Patents awarded drugs
Patents filed drugs

16. Literary Research
Translation of classical books/manuscripts in different languages. 51
Books/brochures/leaflets and IEC material in different languages. 25
Reprint of rare classical books 88
Standardization of Unani Terminology
4000 terms

17. Collaboration/support with other institutions
All India Institute of Medical Sciences, (AIIMS) New Delhi.
Vallabh Bhai Patel Chest Institute, University of Delhi, New Delhi.
Jamia Hamdard (Hamdard University), New Delhi.
KGMC, Lucknow.
Ibn-e-Sina Academy, Aligarh.
Centre of Liver diseases Deccan Med. College, Hyderabad
Taramani Hospital & Res. Centre, Chennai.
Osmania General Hospital Hyderabad.

18. Contd.. Collaboration/support with other institutions
With the financial support by DST for creating research infra-structure two facilities were created:
Clinical Research facilitiy at CRI, Hyderabad.
Pre-clinical research facilitiy at RRI, Srinagar.

19. Collaboration with Foreign Institutions
Centre for Research in Indian Systems of Medicine (CRISM) in University of Mississippi, USA
UNANI CHAIR at University of Western Cape, South Africa
UNANI CHAIR at Sri Lanka is in process

20. Unani Medicine as Adjuvant therapy
Thrust areas:
Immuno-modulation
To prevent drug toxicity
To improve Quality of Life

21. Unani Medicine as Adjuvant therapy
Contd..
Unani Medicine as Adjuvant therapy
Areas
Cognitive impairment
Tuberculosis (especially MDR TB)
Cancer
HIV / AIDS

22. Unani Medicine as Adjuvant therapy
Contd..
Study 1
Cognitive impairment
Title:
Evaluation of a Unani Formulation for Improving Cognitive Impairment in Children with Cerebral Palsy and Mental Retardation
The study was conducted at Majeedia Hospital, Jamia Hamdard in collaboration with UDAAN an NGO working for disabled children.
This was a controlled study in which both groups were given physiotherapy and special education but one group was given Unani formulation and other group HBOT.
The study was conducted on current clinical parameters following the GCP.
Objective:
To prove efficacy of Unani formulation in the treatment of Neurodevelopmental disabilities with special emphases on cognitive improvement in Cerebral Palsy (C.P.) and/or Mental Retardation (M.R.).
Outcome:
Long term amelioration of associated behavioural and neurological problems
Improvement in memory and cognitive functions
Improvement in musculo-skeletal deformities

23. Unani Medicine as Adjuvant therapy
Contd…
Study 2
Title:
Study on management of Pulmonary Tuberculosis with herbal Unani product (0394) as an adjuvant drug .
The study was sponsored by Panacea Biotech and conducted at Majeedia Hospital, Jamia Hamdard, Hamdard Nagar, New Delhi.
This was a controlled study in which ATT was given to both groups and only one group was given Unani adjuvant formulation along with ATT.
The study was conducted on current clinical parameters following the GCP.
Objective:
To evaluate the efficacy of Unani formulation in enhancement of resolution rate in Pulmonary Tuberculosis including MDR.
Outcome:
Fast resolution of infiltration in chest.
Faster sputum clearance for AFB.
Better response in MDR cases.

24. Unani Medicine as Adjuvant therapy
Contd…
Unani Medicine as Adjuvant therapy
Study 3
Title:
Clinical evaluation of a Unani formulation for prevention ofhepato-nephro toxicity in Pulmonary Tuberculosis.
(The study was conducted at Majeedia Hospital, Jamia Hamdard.
This was a controlled study in which both groups were given ATT and one group was Unani Hepato-protective formulation.
The study was conducted on current clinical parameters following the GCP.
Objective:
To evaluate efficacy of Unani formulation in the treatment of Pulmonary Tuberculosis with reference to prevention of hepato-nephro toxicity.

25. Unani Medicine as Adjuvant therapy
Contd…
Unani Medicine as Adjuvant therapy
Cancer
Objective of the study is to prevent the hepato-nephro toxicity during chemotherapy and to improve the Quality of Life in Cancer patients.
Feasibility study has been completed. Detailed planning and protocol designing at CRIUM, Lucknow is under progress.

26. Unani Medicine as Adjuvant therapy
Contd…
Unani Medicine as Adjuvant therapy
HIV / AIDS
Objective of the study is to improve, enhance and potentiate body immunity and to improve the Quality of Life in HIV/AIDS patients.
Feasibility study has been conducted. Detailed planning and protocol designing at RRIUM, Mumbai in collaboration with J.J. Hospital, Mumbai.

27. Thank You